Cover 2 Resources
Cover 2 Resources
Ep. 157 – Pharmaceutical Companies Price Gouge, No Government Oversight: Daniel Denvir
Ep. 157 – Pharmaceutical Companies Price Gouge, No Government Oversight: Daniel Denvir
Ep. 157 – Pharmaceutical Companies Price Gouge, No Government Oversight: Daniel Denvir
Tuesday 9th January 2018
Daniel Denvir discusses how pharmaceutical companies are raising naloxone prices during the opioid crisis on Cover2 Resources. Learn more now.
25 minutes
Informative
Thought-provoking
Raw
Engaging
Transformative
About this podcast
Overview:
Categories:
Innovative Treatments & Recovery Paths
Family Recovery from Addiction
Sobriety Toolkit
Body & Mind
Navigating Intimate Relationships
Links:
Visit site
Episodes:
284 (View all)
Do you want to link to this podcast?
Get the buttons here!Daniel Denvir Exposes Naloxone Price Gouging Amid Opioid Crisis
If this is the crisis that everyone seems to agree that it is, you'd think that the government would be doing everything that it could to lower prices instead of just waiting for the so-called free market to take care of it, because it obviously hasn't.
Ever wondered why life-saving drugs like naloxone are so expensive? In this episode of the Cover2 Resources podcast, Greg McNeil sits down with Daniel Denvir, a Fellow at Harvard Law School’s Fair Punishment Project and host of The Dig podcast, to unravel the troubling issue of naloxone price hikes. Denvir sheds light on how pharmaceutical companies are exploiting the opioid crisis for profit, making it harder for those in need to access this crucial medication.
Denvir points out that as opioid overdoses have surged, so has the price of naloxone, a drug that can reverse overdoses. Despite the growing need, the government has done little to regulate these price increases. Denvir argues that legislation could easily be passed to make naloxone more affordable, but instead, policies seem to favor the interests of wealthy corporations over those of everyday Americans. He highlights the primary culprits behind the price gouging: Adapt and Kaleo.
These companies have significantly raised naloxone prices, putting it out of reach for many. Denvir suggests that introducing more competitors into the market could help drive prices down. He also discusses the practice of co-prescribing naloxone with opioids, noting that while it’s a good idea, it’s often manipulated to maintain high prices. Denvir shares that family members and loved ones of overdose victims are mobilizing to advocate for more accessible naloxone.
He believes that the drug should be available for as little as one to five dollars. This episode not only highlights the problem but also calls for action to make life-saving drugs more affordable and accessible to everyone. Tune in to this eye-opening discussion on the Cover2 Resources podcast to understand the complexities behind naloxone pricing and what can be done to ensure it’s available to those who need it most.